✦ LIBER ✦

6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial

✍ Scribed by Paz-Ares, L.; Pollak, M.N.; Eisenberg, P.D.; Blakely, L.J.; Haluska, P.; Cohen, R.B.; Kreisman, H.; Melvin, C.; Gualberto, A.; Karp, D.

Book ID: 122808409
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 77 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(07)71336-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB

Randomized Phase II Study of Vandetanib

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer

✍ Heymach, J. V.; Paz-Ares, L.; De Braud, F.; Sebastian, M.; Stewart, D. J.; Eberh 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB